TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

U A Matulonis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.